These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17106327)

  • 21. Hormone hazards. Long-term estrogen use may double the risk of ovarian cancer. But look beyond the numbers.
    Gorman C
    Time; 2001 Apr; 157(13):78. PubMed ID: 11299712
    [No Abstract]   [Full Text] [Related]  

  • 22. Hormone replacement. HRT forum: cancer risk.
    Harv Womens Health Watch; 2001 Jun; 8(10):6-7. PubMed ID: 11439283
    [No Abstract]   [Full Text] [Related]  

  • 23. Postmenopausal hormone therapy and risk of breast cancer.
    Chen FP
    Chang Gung Med J; 2009; 32(2):140-7. PubMed ID: 19403003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of ovarian cancer in the Million Women Study.
    Neves-E-Castro M
    Gynecol Endocrinol; 2007 Jul; 23(7):410-3. PubMed ID: 17701773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does HRT promote ovarian cancer?
    Health News; 2001 May; 7(5):8. PubMed ID: 11851163
    [No Abstract]   [Full Text] [Related]  

  • 27. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy.
    Hoffmeister M; Raum E; Krtschil A; Chang-Claude J; Brenner H
    Clin Pharmacol Ther; 2009 Oct; 86(4):416-24. PubMed ID: 19606090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
    Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
    Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
    Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
    Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer and hormonal therapy.
    Conner P; Lundström E; von Schoultz B
    Clin Obstet Gynecol; 2008 Sep; 51(3):592-606. PubMed ID: 18677153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone replacement therapy and prognosis in ovarian cancer patients.
    Hein A; Thiel FC; Bayer CM; Fasching PA; Häberle L; Lux MP; Renner SP; Jud SM; Schrauder MG; Müller A; Wachter D; Strehl J; Hartmann A; Beckmann MW; Rauh C
    Eur J Cancer Prev; 2013 Jan; 22(1):52-8. PubMed ID: 22694828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormone replacement therapy after endometrial or ovarian cancer].
    Daraï E; Gompel A; Deval B; Laplace C; Lemoine A; Labeyrie E; Neu AM; Poitout P
    Gynecol Obstet Fertil; 2000 Mar; 28(3):198-204. PubMed ID: 10786400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of estrogen-progestin and estrogen on mammographic density.
    Kaewrudee S; Anuwutnavin S; Kanpittaya J; Soontrapa S; Sakondhavat C
    J Reprod Med; 2007 Jun; 52(6):513-20. PubMed ID: 17694969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
    Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
    Windler E; Zyriax BC; Eidenmüller B; Boeing H
    Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian failure following cancer treatment: current management and quality of life.
    Absolom K; Eiser C; Turner L; Ledger W; Ross R; Davies H; Coleman R; Hancock B; Snowden J; Greenfield D;
    Hum Reprod; 2008 Nov; 23(11):2506-12. PubMed ID: 18664468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.